Toward more efficient clinical trials for amyotrophic lateral sclerosis
- 4 December 2009
- journal article
- review article
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis
- Vol. 11 (3) , 259-265
Abstract
More than 30 phase II or III clinical trials have been carried out in amyotrophic lateral sclerosis (ALS). Only riluzole, however, has been shown to extend survival and/or time to tracheostomy. Many early ALS trials lacked solid pharmacodynamic and pharmacokinetic data for the treatment being tested, challenging the interpretation of the efficacy and pathway relevance. Understanding of the genetics and pathophysiology of ALS has improved considerably in the past decade, but biomarkers of disease activity remain lacking. A more efficient approach to early phase clinical trials is needed to accelerate the identification of useful agents for ALS. Here we summarize our current thinking about phase II design options and the potential benefits of a clinical trial network for phase II trials in ALS.Keywords
This publication has 18 references indexed in Scilit:
- Subcutaneous IGF-1 is not beneficial in 2-year ALS trialNeurology, 2008
- Lithium delays progression of amyotrophic lateral sclerosisProceedings of the National Academy of Sciences, 2008
- Design of phase II ALS clinical trialsAmyotrophic Lateral Sclerosis, 2008
- A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALSAmyotrophic Lateral Sclerosis, 2008
- Impact of amyloid imaging on drug development in Alzheimer's diseaseNuclear Medicine and Biology, 2007
- Phase II/III randomized trial of TCH346 in patients with ALSNeurology, 2007
- PTC124 targets genetic disorders caused by nonsense mutationsNature, 2007
- Trial of celecoxib in amyotrophic lateral sclerosisAnnals of Neurology, 2006
- An Overview of the Bayesian Approach2003
- Polishing, sensing, switching and synthesizing.Nature Materials, 2003